PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Glia. Author manuscript; available in PMC 2013 November 1.
Published in final edited form as:
PMCID: PMC3604747
NIHMSID: NIHMS386652

Astrocytic Cx43 hemichannels and gap junctions play a crucial role in development of chronic neuropathic pain following spinal cord injury

Abstract

Chronic neuropathic pain is a frequent consequence of spinal cord injury (SCI). Yet despite recent advances, up-stream releasing mechanisms and effective therapeutic options remain elusive. Previous studies have demonstrated that SCI results in excessive ATP release to the peri-traumatic regions and that purinergic signaling, among glial cells, likely plays an essential role in facilitating inflammatory responses and nociceptive sensitization. We sought to assess the role of connexin 43 (Cx43) as a mediator of CNS inflammation and chronic pain.

To determine the extent of Cx43 involvement in chronic pain, a weight-drop SCI was performed on transgenic mice with Cx43/Cx30 deletions. SCI induced robust and persistent neuropathic pain including heat hyperalgesia and mechanical allodynia in wild-type control mice, which developed after 4 weeks and was maintained after 8 weeks. Notably, SCI-induced heat hyperalgesia and mechanical allodynia were prevented in transgenic mice with Cx43/Cx30 deletions, but fully developed in transgenic mice with only Cx30 deletion. SCI-induced gliosis, detected as upregulation of glial-fibrillary-acidic- protein (GFAP) in the spinal cord astrocytes at different stages of the injury, was also reduced in the knockout mice with Cx43/Cx30 deletions, when compared to littermate controls. In comparison, a standard regimen of post-SCI treatment of minocycline attenuated neuropathic pain to a significantly lesser degree than Cx43 deletion.

These findings suggest Cx43 is critically linked to the development of central neuropathic pain following acute SCI. Since Cx43/Cx30 is expressed by astrocytes, these findings also support an important role of astrocytes in the development of chronic pain.

Keywords: Astrocyte, ATP, chronic pain, Connexin 43, P2X, spinal cord injury

Introduction

As many as 80% of patients who suffer spinal cord injury (SCI) experience chronic pain that develops shortly following the primary injury and often persists indefinitely. Chronic pain of this nature is distinct from acute pain in that it provides no neuroprotective benefits with its negative effects lasting long after the injury site has healed, (Hulsebosch et al. 2009; Norenberg et al. 2004; Turner and Cardenas 1999). Recent progress in the field of pain research has demonstrated important roles of spinal cord glial cells (e.g. microglia and astrocytes), in the genesis of chronic pain (Gao and Ji 2010; Milligan and Watkins 2009; Tsuda et al. 2005). It is generally believed that activation of glial cells induces central sensitization and enhances chronic pain via producing glial mediators, such as pro-inflammatory cytokines (IL-1β, IL-6, TNF – α) (DeLeo and Yezierski 2001; Kawasaki et al. 2008; Watkins et al. 2001). Activation of ATP receptors such as P2X7 receptors in microglia is essential for the release of pro-inflammatory cytokines (Clark et al. 2010). However, the cellular source of ATP and the molecular mechanisms controlling ATP release are still elusive.

Initial astrocyte and microglial activation is thought to represent a generalized neuro-protective response aimed at ameliorating the damage done by the initial spinal cord injury (Bethea 2000; Farahani et al. 2005; Faulkner et al. 2004). However, if activation goes unopposed, a secondary phase of reactive gliosis occurs that triggers cell death among neurons and glia, and is associated with peritraumatic expansion of neural damage (Bethea 2000; Springer et al. 1999). This secondary phase has been shown to correlate with high levels of sustained ATP release, in the peritraumatic regions (Wang et al. 2004). Although the source of ATP remains controversial, high extracellular levels have been shown to activate purinergic P2X receptors on microglia and leukocytes, and P2X7 activation in particular has been shown to contribute to the secretion of a host of cytokines and pro-inflammatory molecules (e.g. ROS, IL-1β, IL-6, TNF – α, etc.) (Collo et al. 1997; Di Virgilio et al. 2009; Di Virgilio et al. 1999; Peng et al. 2009). Exposure to cytokines is known to contribute to neuronal sensitization in the spinal cord and is also thought to contribute to chronic pain (Cotrina and Nedergaard 2009; Gwak and Hulsebosch 2011; Kawasaki et al. 2008). Furthermore, pharmacological blockade and genetic deletion of P2X receptors have been shown to attenuate rodent pain-like- behaviors, which suggest that activation of cell P2 receptors is an essential step in the development of chronic pain. (Chessell et al. 2005; Dell'Antonio et al. 2002a; Dell'Antonio et al. 2002b; Labasi et al. 2002; Tsuda et al. 2009). A more in depth understanding of the causes and consequences of ATP release in the setting of spinal cord injury is, therefore, of great clinical importance, as it would allow specific targeting for novel therapies.

We have previously shown that ATP is released after spinal cord injury (Peng et al. 2009) and that genetic deletion of connexin 43 (Cx43), a principle connexin expressed in spinal cord astrocytes, dramatically decreases the extracellular concentration of ATP following acute SCI (Huang et al. 2012). Unopposed hemichannels that directly link the cytosol and the interstitium (Bennett et al. 2003; Kang et al. 2008) constitute ideal candidates for potential ATP release pathways, since the biophysical profile of these channels shows them to be capable of high levels of ATP efflux (Bennett et al. 2003; Cotrina et al. 1998; Parpura et al. 2004). Studies have also shown that astrocytes upregulate the expression of Cx43 following traumatic SCI (Theriault et al. 1997) and that exposure to several types of cytokines reduces astrocyte-astrocyte gap junctional communication (Contreras et al. 2002; Meme et al. 2006; Retamal et al. 2007). Additionally, blocking the expression of Cx43 has been shown to attenuate inflammation and improve functional recovery following SCI (Cronin et al. 2008), which further implicates Cx43 as a mediator of reactive changes following injury. Here we sought to evaluate the role of Cx43 in chronic neuropathic pain and inflammation, as it is well established that purinergic signaling plays a role in acute pain transmission and pro-inflammatory cytokine release.

The aim of this study was to evaluate the role Cx43 plays in the development and maintenance of chronic pain following spinal cord injury. We show that transgenic mice with deletions of both Cx43 and Cx30 exhibited improved pain scores, and reduced up-regulation of GFAP following spinal cord injury, as compared to controls.

Materials and Methods

Animals

In addition to wild-type C57BL/6 (Charles River) mice, Cx30−/−Cx43fl/fl:hGFAP–Cre (Cx43−/−Cx30−/−, double knockout) and their litter mate controls, Cx30−/−Cx43fl/fl (Cx30−/− single KO), which were originally generated in 2006 (Wallraff et al. 2006), were used in evaluating the role of Cx43 on chronic pain development. All mice were 8–10 week females with a weight of 20–25 grams. In addition, C57BL/6 (Charles River) age-matched female mice were used for the minocycline studies. In accordance with UCAR protocol, animals were housed under a 12 hour light-dark cycle and had free access to water and food. All experiments were approved by the Animal Care and Use Committee of the University of Rochester.

Surgery

Adult female mice were anesthetized with a mixture of ketamine (60mg/kg, i.p.) and xylazine (10mg/kg, i.p.). A laminectomy over the dorsal portion of T11 was performed and the vertebral column was held with fine clamps at the T10 and T12 level. The exposed dorsal surface of the spinal cord was subjected to a 3g weight-drop with tip diameter of 0.5 mm flat surface, modified NYU impactor (Peng et al. 2009), from a height of 6.75mm using a modified NYU impactor. Accordingly animals were monitored post-SCI via BMS scoring and de-urinated twice a day until leg movement returned to animals.

Behavioral Studies

Mechanical allodynia and heat hyperalgesia were examined over the course of two months after spinal cord injury to determine the development of SCI-induced neuropathic pain. Mechanical allodynia was tested using Von Frey Filaments. Each session involved the exertion of a filament with 0.02g of force onto the plantar surface of the foot. The percentages of negative responses were calculated for each foot. A total of 10 trials were done per day (Goldman et al. 2010).

Heat hyperalgesia was evaluated using Plantar Test (Ugo Basile). The Plantar test apparatus was calibrated before and after each set of data to ensure accuracy. A mobile heat source was placed under the hind paw and calibrated to an IR intensity of 20. Paw withdrawal latency was defined as the time taken by a mouse to withdraw its foot from radiant heat. Each foot was measured 3 times, giving an average. To avoid conditioning to stimulation there was a 5 minute rest period between each measurement. Furthermore, to account for stress to the environment, each animal was allowed to habituate for one hour before any measurements were taken (Goldman et al. 2010).

Tissue Preparation

The mice were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) and perfused transcardially with 4% paraformaldehyde in PBS at 8 weeks after SCI. The spinal cords were dissected, postfixed overnight at 4 °C, and then transferred to 30% sucrose for processing into 20 µm longitudinal cryosections. One set of sections was stained with cresyl violet, and the remaining sections were used for immunohistochemistry. These sections were blocked for 30 min at room temperature in a solution containing 10% normal donkey serum and 0.5% Triton X-100, and incubated overnight at 4 °C with primary antibodies against GFAP (1:500, Sigma), and Cx43 (1:500, Sigma). All fluorescent- conjugated secondary antibodies (Jackson Immunoresearch) were used at 1:250. After immunolabeling, the sections were counterstained with DAPI (1:5000, Invitrogen) for 10 min at room temperature and a coverslip mounted. Images were collected with a confocal microscope (FV500, Olympus) with FluoView (Olympus) software by using a 20x oil objective lens (NA 1.3). Nonbiased image collection was used to evaluate the injury volume and fluorescence intensity (see below). Images were subsequently analyzed with custom-made MatLab software (Peng et al. 2009). Since mild injury was studied, no obvious tissue lesions were identified in the spinal cords harvested 2 months after the traumatic injury. Instead, the spinal cords exhibited clear atrophy close to the site of impact. The spinal cord atrophy volume was quantified as the tissue missing in serial longitudinal sections of the spinal cord stained with cresyl violet as shown in Fig. 2. For immunohistochemical analysis, four to six fields (640 - 640 microns2) (2–3 from rostral left and right and 2–3 from caudal left and right) of gray and white matter were chosen as the near injury fields; 4–6 fields at least 10-mm distance from the site of injury were likewise chosen as distant fields. The parameters for confocal image capture (laser, power, photomultiplier tube voltage, gain, and offset) were set from a wild-type spinal cord and remained constant for all remaining image capturing. The average intensity of each field (intensity per um2) was quantified, and the data were expressed as % intensity increase in near-injury area with respect to the far-injury area.

Fig. 2
Deletion of Cx43 does not significantly change lesion volume or locomotor recovery following mild spinal cord injury

Results

Littermate controls express CX43 on GFAP expressing cells while Cx43/Cx30 KO do not

It has been well established that Cx43 is well expressed in spinal cord astrocytes (Huang et al. 2012). However to confirm that our model was appropriate, double immunohistochemistry staining of Cx43 and GFAP demonstrated co-localization of Cx43 expression with astrocytic cells (GFAP expressing cells) in littermate controls (Fig. 1). Consistent with previous findings we found that Cx43 levels and plaque formation were elevated in injured animals when compared to non-injury site in littermate controls (Theriault et al. 1997). Meanwhile double immunohistochemistry staining of Cx43 and GFAP in Cx43/Cx30 KO confirmed that Cx43 was not present at injury sites or non-injured sites, confirming our transgenic animal (Fig. 1).

Fig. 1
Immunohistochemical staining of injured and noninjured spinal cord

Exposure to mild spinal cord injury results in impaired locomotor function and loss of spinal cord tissue in both wild-type and knockout mice

Connexin 43 (Cx43) is recognized as the primary gap junctional protein expressed by astrocytes (Teubner et al. 2003; Theis et al. 2003). To delete Cx43 in astrocytes, we used a mouse line developed by Klaus Willecke in which conditional knockout in astrocytes is accomplished using mice expressing Cre under the human glial fibrillary acidic protein (hGFAP) promoter (Theis et al. 2001). However, astrocytes also express connexin 30 (Cx30), and Cx30 has been reported to exhibit a compensatory upregulation in response to deletion of Cx43 (Nagy et al. 1999; Teubner et al. 2003; Theis et al. 2003). To prevent compensatory increases in Cx30 expression, the Cx43 mice were therefore crossed with Cx30 knockout mice. We compared double-deficient Cx30 −/−, Cx43 fl/fl: GFAP-Cre (double knockouts) with their littermate, Cx30 −/−, Cx43 fl/fl (Cx30 KO) and wild type controls (WT) to evaluate the roles of astrocytic Cx43 hemichannels/gap junctions in the development of SCI-induced neuropathic pain.

All mice were exposed to mild spinal cord injury (3g weight with tip diameter of 0.5 mm dropped from a height of 6.75mm)(Fig. 2A). Motor behavior was assessed on a biweekly schedule in open-field testing with the aid of the 9 -point Basso Mouse Scale for Locomotion (BMS) rating scale after traumatic SCI (Fig. 2B). All measurements were taken at the same time of day during the wake cycle of the animal (Basso et al. 2006; Beare et al. 2009). No significant difference was found between Cx43/Cx30 mice and the littermate controls in the BMS scoring during the two months observation period (P-value > 0.05) (Fig. 2B). Immediately after spinal cord injury, all animals displayed scores of 0–2, signifying complete paraplegia with movement limited to slight ankle movement. Both Cx43/Cx30 KO and their littermates exhibited steady recovery with partial recovery of motor function over a period of 4–5 weeks after injury (BMS score > 5, which correlates with the first signs of plantar placement defined, as thumb and last toe of paw placed on surface with each step) (Fig. 2A).

A milder injury induced via weight drop was selected to ensure that the injury was accompanied with extensive functional recovery (BMS score) and to ensure proper recovery of somatosensory function (Rosenzweig et al. 2010). As the focus of this study was on chronic pain development, extensive functional recovery is crucial to prevent permanent paraplegia. As a consequence of this mild injury, no clear lesions could be identified in longitudinal sections of the spinal cord after weight drop injury. Instead, we quantified atrophy volume in Cx43/Cx30 KO and their littermate controls exposed to the same injury (Fig. 2C). Spinal cord atrophy was quantified in cresyl violet-stained serial longitudinal sections of the spinal cord, as shown in Fig.2 and previously described (Peng et al. 2009).

Littermate controls and WT Controls exhibit indistinguishable neuropathic pain following spinal cord injury (SCI)

As the study was focused on Cx43 in astrocytes, the first step is to confirm that Cx30 KO and wild type controls are indistinguishable in regards to chronic pain development. We first observed baseline pain sensitivity between Cx30 KO mice and wild type controls. We found that mechanical allodynia (Fig. 3A) and heat hyperalgesia (Fig. 3B) are not significantly different at baseline (p > 0.05). We next observed chronic pain development following SCI. We found that mechanical allodynia (Fig. 3A) and heat hyperalgesia (Fig. 3B) following SCI injury are also not significantly different (p > 0.05). Following this confirmation, we compared Cx43/Cx30 double KO with their littermate controls, exclusively, as no significant difference was found between Cx30 and wild type controls or littermate controls and wild type controls.

Fig. 3
Cx30 KO plays no role in the development in chronic pain after spinal cord injury

Cx43/Cx30 KO mice do not develop neuropathic pain following spinal cord injury (SCI)

We first compared baseline pain sensitivity in Cx43/Cx30 KO mice and littermate controls before SCI. We found that mechanical paw withdrawal frequency to mechanical von frey filament (0.02g) stimulus (Fig. 4A) and paw withdrawal latency to radiant heat stimulus (Fig. 4B) were almost identical in Cx43/Cx40 KO and littermate control, indicating normal pain perception in both strains.

Fig. 4
Deletion of Cx43 reduced mechanical allodynia and heat hyperalgesia after mild spinal cord injury

Neuropathic pain after SCI is characterized by mechanical allodynia, nociceptive response to previously innocuous low-threshold mechanical stimulus (Tan et al. 2009). We assessed the development of mechanical allodynia weekly for 8 weeks. As a result of the paraplegia, during the first 3 weeks after injury, no allodynia was observed (Fig. 4A). Four weeks following spinal cord injury or at the time point where the mice started to regain significant motor functions (BMS score 4 or higher), littermate mice began to develop mechanical allodynia, which was still maintained after 8 weeks. However, SCI-induced mechanical allodynia was prevented in Cx43/Cx30 KO mice. From week 4 to 8, Cx43/Cx30 KO mice consistently exhibited significantly higher negative mechanical nociceptive response rate than their littermate controls (p<0.05) (Fig. 4A). At the last time point evaluated (2 months after SCI), negative response rate decreased from 90% ± 1.9% to 40 ± 4.29% in littermate controls but only from 86.67 ± 2.9% to 72.2 ±6.9% in Cx43/Cx30 KO mice.

In addition to mechanical allodynia, SCI-induced neuropathic pain is also characterized by heat hyperalgesia, which is defined as an increased response to a noxious heat stimulus. In the first 3 weeks after SCI, prior to motor recovery, no significant difference in heat sensitivity was noted between Cx43/Cx30 KO mice and their littermate controls (p>0.1). However after partial motor recovery at 4 weeks, heat nociceptive threshold levels (withdrawal latencies) were significantly higher in CX43/Cx30 KO mice when compared to littermate controls (Fig. 4B). At the last time point evaluated (two months after SCI), paw withdrawal latency decreased from 13.03 ± 0.60 seconds to 3.22 ± 0.54 seconds in litter mate controls (p < 0.05), but only decreased from 12.93 ± 0.85 seconds to 9.88± 0.66 seconds in Cx43/Cx30 KO mice (p>0.1) (Fig. 4B).

Minocycline moderately reduces neuropathic pain following SCI less efficiently than deletion of Cx43/Cx30

The effect of minocycline, an anti-inflammatory agent and also a microglia inhibitor, on the development of neuropathic pain following SCI was next evaluated (Hains and Waxman 2006; Marchand et al. 2005). A standard regimen consisting of daily injections of 0.3 ml minocycline (50 mg/kg, i.p) or saline (control littermates) were given to C57/Bl wild-type animals for 5 consecutive days following SCI (Tan et al. 2009). Weekly analysis of heat hyperalgesia and mechanical allodynia in the first 3 weeks after mild spinal cord injury showed no effects of minocycline on these neuropathic pain behaviors (Fig. 5A, B). However, after 4 weeks, or upon the recovery of motor function (defined as BMS score of >4), the animals treated with minocycline exhibited significantly less mechanical allodynia (p < 0.05) (Fig. 5A) and heat hyperalgesia (p <0.01) (Fig. 5B).

Fig. 5
Minocycline also reduces the development of neuropathic pain symptoms after mild spinal cord injury, but less efficiently than deletion of Cx43

Deletion of Cx43/Cx30 more robustly reduced both mechanical allodynia and heat hyperalgesia than minocycline (p <0.01) (Fig. 5C, D). A comparison of the efficacy by which the two manipulations reduced allodynia showed that deletion of Cx43/Cx30 consistently reduced allodynia more than minocycline treatment. The comparison was performed after normalization of the hyperalgesia and allodynia scores to corresponding controls. While minocycline reduced mechanical allodynia (% of response) by 1–30%, after being normalized to corresponding vehicle control, Cx43/Cx30 deletion reduced mechanical allodynia (% of response) by 1 – 200%, after being normalized to littermate control (Fig. 5C). Moreover, minocycline only changed heat hyperalgesia (paw withdrawal latency) by 1–40%, while Cx43/Cx30 deletion changed heat hyperalgesia by 1–300%, after being normalized to corresponding controls (Fig. 5D). This suggests that targeting Cx43/Cx30 hemichannel/gap junctions is more effective in reducing the development of neuropathic pain than administration of minocycline, a traditional anti- inflammatory agent (Fig. 5C, D).

Deletion of Cx43/Cx30 reduces the severity of reactive gliosis in the injured spinal cord

To evaluate the role of Cx43/Cx30 KO in reactive gliosis, immunohistochemisty was next used to quantify GFAP expression in the peri-traumatic areas at various time points after spinal cord injury. Immunolabeling revealed that 3 day post-SCI littermate control mice significantly higher levels of GFAP immunoreactivity in the peri-traumatic regions in contrast to Cx43/Cx30 KO controls (p<0.05, student t-test). GFAP expression peaked seven days post-SCI with littermate controls mice exhibiting significantly higher GFAP expression than Cx43/Cx30 KO mice (p<0.05, student t-test). GFAP expression began to decline from the peak by 1 month post-SCI. However, littermate controls continued to show increased GFAP expression than Cx43/Cx30 KO (p<0.05, student t-test) (Fig. 6 A, B). Thus GFAP expression in the peri-traumatic areas was significantly reduced in Cx43/Cx30 KO mice, suggesting that Cx43 play a role in astrogliosis after spinal cord injury. In addition to GFAP, slices were stained for Iba1. Littermate controls exhibited significantly higher fluorescent intensity of Iba1 when compared with Cx43/Cx30 KO mice. Iba1 intensity peaked 3 day post-SCI and declined by 1 month post-SCI (data not shown). This is consistent with the literature as only GFAP expression remains elevated 6–8 weeks after SCI (Peng et al. 2009). Other markers of inflammation, including CD68 (microglia activation), MPO (neutrophils), and CD8 (cytotoxic T-lymphocytes) normalized to pre-injury level within a few weeks after traumatic injury of the spinal cord (data not shown).

Fig. 6
Deletion of Cx43 reduced astrogliosis after mild spinal cord injury

Discussion

The present study demonstrates, for the first time, that astrocytic connexin 43 (Cx43) plays an essential role in the development of chronic neuropathic pain following spinal cord injury (SCI). Prior studies have demonstrated that ATP activation of spinal glia via P2X receptors represents a critical step in the development and facilitation of chronic pain (Di Virgilio et al. 2009; Ferrari et al. 2006; Milligan and Watkins 2009). A major driving force in this process consists of the release of pro- inflammatory molecules such as cytokines, which can sensitize neurons and exacerbate pathological plasticity following injury (Di Virgilio et al. 1999; Gwak and Hulsebosch 2011; Hughes et al. 2007). We propose that Cx43 mediated ATP release constitutes a critical upstream pathway that facilitates the development of chronic pain. Using a weight drop injury model, we show that transgenic mice with Cx43/Cx30 deletion, exhibited significantly reduced neuropathic pain and reduced levels of gliosis, when compared to littermate controls and wild type controls exposed to the same injury (Fig. 4 and and5).5). These findings, to date, appear to identify the furthest upstream step involved in purinergic-mediated chronic pain and, therefore, suggest that effective therapeutic targets may be found immediately downstream from ATP release.

In addition, increases in extracellular ATP have been documented in a wide range of peripheral and central nervous system injuries, such as sciatic nerve entrapment (Matsuka et al. 2008), traumatic brain injury (Davalos et al. 2005; Franke et al. 2006), and various models of SCI (Peng et al. 2009; Wang et al. 2004). Spinal astrocytes, which are in close contact with neuronal synapses, have been shown to respond to SCI-induced changes by releasing gliotransmittors and neuromodulators, such as ATP and glutamate (Thompson et al. 2006; Ye et al. 2003). More interestingly, peri-traumatic regions have also been shown to exhibit ATP release, that lasts more than 6 hours (Wang et al. 2004), suggesting the presence of a continuous release pathway from viable ATP-producing cells; one possible source being gap junction-coupled networks of astrocytes with an increased number of open hemichannels. Bioluminescent imaging of cells in culture, and two-photon imaging in vivo (Newman 2005) have shown that ATP release through connexin hemichannels triggers astrocytic activation via calcium waves (Bennett et al. 2003). These calcium waves have been implicated as a feedback mechanism in response to traumatic injury (Neary et al. 2003), and have been shown to trigger additional ATP release (Gallagher and Salter 2003; Scemes and Giaume 2006; Suadicani et al. 2004).

Furthermore, for several decades, ATP has been known to elicit pain responses when applied to the skin or peripheral nerves and, more recently, ATP was found to play a critical role in pain transmission, through its role as a fast neurotransmitter among nociceptive neurons in the dorsal horn (Brederson and Jarvis 2008; Chen and Gu 2005; Kennedy 2005). Extracellular ATP is also an important mediator of CNS inflammation, through action on glial P2 receptors (Gwak and Hulsebosch 2011; Hughes et al. 2007; Milligan and Watkins 2009). Although little is known about the role of P2Y metabotropic receptors in chronic pain (Kobayashi et al. 2008; Tozaki-Saitoh et al. 2008), the P2X subfamily of ATP receptors are heavily expressed on microglia and leukocytes (Collo et al. 1997) and, P2X7 in particular has been shown to facilitate the maturation and secretion of pro-inflammatory cytokines and other signaling molecules (e.g. ROS, IL-1, IL-6B, TNF, etc.) that contribute to neuronal sensitization and chronic pain (Di Virgilio et al. 2009; Ferrari et al. 2006; Minami et al. 2006). Additionally, blockade or deletion of P2X7 has been shown to decrease cytokine production and secretion (Gourine et al. 2005; Solle et al. 2001), attenuate neuropathic and inflammatory pain(Dell'Antonio et al. 2002a; Dell'Antonio et al. 2002b; Labasi et al. 2002; Sorge et al. 2012), and promote functional recovery following SCI (Peng et al. 2009; Wang et al. 2004). P2X4 has also been implicated in chronic pain, and its expression has been shown to upregulate following peripheral nerve injury, while pharmacological blockade and genetic deletion attenuated tactile allodynia (Tsuda et al. 2009; Tsuda et al. 2003). Cx43/Cx30 deletions were expected to inhibit microglial activation and, thereby, cytokine release, via preventing astrocytic release of ATP, which may also exert direct action on neuronal P2X receptors. Our finding that these deletions improved pain scores is, therefore, consistent with a microglial and cytokine-mediated model of chronic pain that is downstream from astrocytic ATP release.

Thus we theorize that astrocytic hemichannels are one of the key sources of ATP after injury. While it is true that, in addition to efflux from unopposed connexin hemichannels, vesicular exocytosis (Garre et al. 2010), opening of pannexin hemichannels (Iglesias et al. 2009), and release from P2X7R (Duan et al. 2003) have been proposed as possible candidates for ATP release, in a previous study, our lab used in vivo bioluminescent imaging to demonstrate a significant reduction in ATP release, in mice with Cx43 deletions, but not in littermate controls, following SCI (Huang et al. 2012). This finding demonstrated the crucial role Cx43 plays in SCI-induced ATP efflux. Additionally, considerable further evidence points to Cx43 as a likely candidate for ATP release since, 1) the inner pore diameter of Cx43 hemichannels is consistent with the passage of ATP, and Cx43 is shown to open under conditions of reduced extracellular Ca2+, ischemia, and metabolic strain (John et al. 1999; Kang et al. 2008; Retamal et al. 2007), 2) astrocytic upregulation of GFAP, which is representative of gliosis, correlates with up-regulation of Cx43, at the site of the injury and in peri-traumatic tissues, which also coincides with increased concentrations of extracellular ATP (Contreras et al. 2002; Retamal et al. 2007; Theriault et al. 1997), and 3) several studies have shown that injury-induced upregulation of Cx43 corresponds to a diminishing of normal gap-junctional communication (Contreras et al. 2002; Garre et al. 2010). These observations are consistent with the hypothesis that upregulation of Cx43 corresponds to the addition of hemichannels capable of ATP efflux.

In addition to Cx43 hemichannels, Cx43 gap junctions could also play a key role in modulating chronic pain. Gap junctions allow for communication between cells via exchange of ions and small molecules that act as secondary messengers, such as Ca2+, NAD+, cAMP, IP3, ATP, glutamate, and glucose (Bennet et al., 2003; Evans et al., 2006) As they are highly expressed by spinal cord astrocytes, they are in an ideal location to modulate chronic pain following spinal cord injury. Hightened astrocyte-astrocyte communication following SCI, through gap junction networks, may result in extensive Ca2+ waves, and long range signaling via the release of ATP. This could directly excite nociceptive neurons, by binding to neuronal P2 receptors, in addition to causing the glial-mediated release of proinflammatory cytokines or pronociceptive molecules, such as ATP, prostaglandin or glutamate, in local or peritraumatic tissue (Evans et al. 2006; Stout et al. 2002; Wu et al. 2012). Furthermore, decoupling of gap junctions has been previously shown greatly reduced the concentrations of IL-1 and IL-6 in tissues and in the CSF, which as a result inhibited the development of mechanical allodynia and heat hyperalgesia after nerve injury (Spataro et al. 2004). In other studies, decoupling of gap junctions has been linked to a reduction in astrocytic activation in the spinal cord, which has also been shown to result in inhibition of mechanical allodynia and heat hyperalgesia (Roh et al. 2010). Although our current mouse model cannot dissect the roles of Cx43 hemichannels and Cx43 gap junctions, both likely have mechanisms that contribute to chronic pain.

As a measure of comparison, administration of minocycline, following a standard protocol (Tan et al. 2009), attenuated mechanical allodynia and heat hyperalgesia (Fig. 5 A, B) but to a much lesser degree than deletion of Cx43/Cx30 (Fig. 5 C, D). In the past decade, minocycline, a tricyclic antibiotic, has been shown to attenuate inflammation and tissue loss following acute SCI, by preventing the activation of microglia (Ledeboer et al. 2005; Lee et al. 2003; Raghavendra et al. 2003). Although the mechanism for its action remains ill-defined, minocycline’s anti- inflammatory effects have also been shown to attenuate chronic pain (Hua et al. 2005; Nie et al. 2010). Given that minocycline is thought to partially derive its anti-inflammatory and anti-nociceptive effects from a similar, albeit, downstream pathway from astrocytic ATP release, we sought to compare its anti- nociceptive effects with those from Cx43/Cx30 deletion. Our finding, that treatment with a standard regimen of minocycline attenuated pain behaviors to a lesser degree than Cx43/Cx30 deletion, is consistent with a microglial driven model of chronic pain downstream from astrocytic release of ATP. This finding also suggests that future therapeutic interventions, which target upstream events (i.e. ATP release or purinergic receptors), may be more efficient than those targeting more complicated downstream pathways, where redundancies in pain signaling are more likely to occur.

No significant difference was found in the BMS scoring, or in atrophy volume, between Cx43/Cx30 KO mice and littermate controls, and additionally atrophy volume did not correlate with reductions in chronic pain development. This finding is not surprising, since it is unlikely that initial tissue loss directly controls the development of chronic pain, which appears to be regulated by different processes, such as long-term glial-neuron interactions or the formation of aberrant nociceptive synapses, following non-laminal-specific axonal regeneration (Tang et al. 2007). Follow-up studies on human SCI have also shown no correlation between injury completeness and chronic pain (Siddall et al. 2003)[82]. Although Cx43 inhibition, or expression interference, has been observed to promote tissue sparing (Cronin et al. 2008; O'Carroll et al. 2008), this may be indirectly due to the disruption of P2X-mediated cytokine release, or more directly due to the effective uncoupling of astrocytic networks. Regardless, it is important to note that Cx43 itself is not likely a potential target for neuroprotection, since 1) No BBB-permeable connexin inhibitors exist and all existing connexin inhibitors are nonspecific, and 2) Cx43 is widely expressed outside the CNS, especially in the heart (Rohr 2004). Better candidates for neuroprotection, as well as for chronic pain, are the recently described P2 receptor antagonists (Donnelly-Roberts and Jarvis 2007; Matasi et al. 2011), which are presently undergoing clinical trials for rheumatoid arthritis and chronic pain (Friedle et al. 2010).

Preliminary findings have also implicated P2Y6 and P2Y12 in the facilitation of chronic pain (Koizumi et al. 2007), although further investigations are needed to define the full extent of their involvement. P2Y receptors expressed by activated spinal cord microglia may contribute to microgliosis, since ATP is known to cause microgliosis in the spinal cord (Chen et al. 2010). Similarly, our data suggest that ATP release is further required for astrogliosis in the spinal cord and that gliosis could be associated with inflammatory mediator production and chronic pain states.

The present findings demonstrate that Cx43 gap junctions and hemichannels are critically involved in the development and maintenance of chronic neuropathic pain. Following acute SCI, heat hyperalgesia and mechanical allodynia were significantly attenuated in mice with Cx43/Cx30 deletions, and this attenuation was found to be greater than that of mice treated with minocycline. The antinociceptive effects of Cx43/Cx30 deletions are consistent with a reduction in ATP release, and thus, the disruption of downstream pathways previously implicated in chronic pain. Taken together, our finding demonstrates that chronic pain is strongly regulated by Cx43 gap junctions and hemichannels and those future therapeutic solutions might be made more effective by targeting downstream pathways, such as the ATP- induced activation of glial P2 receptors.

Acknowledgements

This study was sponsored by NINDS/NIH. We thank Justin Chan for custom Matlab software and Klaus Willecke for providing transgenic mice.

List of abbreviations

SCI
spinal cord injury
Cx43
Connexin 43
Cx30
Connexin 30
GFAP
glial fibrillary acidic protein
ATP
adenosine triphosphate
ROS
reactive oxygen species
IL-1β
interleukin-1 beta
IL-6
interleukin-6
TNF-α
tumor necrosis factor-alpha
DAPI
4',6-diamidino-2-phenylindole
ERK
extracellular receptor kinase
BBB
blood brain barrier
CNS
central nervous system
BMS
Basso mouse scale

Footnotes

Statistical Analysis:

All data are plotted as mean ± SEM. Student t-test (2-tailed, unpaired) and one-way ANOVA were used in all data comparison. Data was graphed using Adobe Illustrator and Adobe Photoshop.

Competing Interests:

We have no competing interests to declare.

Author Contributions

WP carried out the surgeries and analysis of the atrophy volume, whereas WP, BK, and MC collected behavioral data. KM carried out the immunohistological staining of the spinal cords. MC, BK, RRJ and MN conceived the study and drafted the manuscript.

References

  • Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma. 2006;23(5):635–659. [PubMed]
  • Beare JE, Morehouse JR, DeVries WH, Enzmann GU, Burke DA, Magnuson DS, Whittemore SR. Gait analysis in normal and spinal contused mice using the TreadScan system. J Neurotrauma. 2009;26(11):2045–2056. [PMC free article] [PubMed]
  • Bennett MV, Contreras JE, Bukauskas FF, Saez JC. New roles for astrocytes: gap junction hemichannels have something to communicate. Trends Neurosci. 2003;26(11):610–617. [PMC free article] [PubMed]
  • Bethea JR. Spinal cord injury-induced inflammation: a dual-edged sword. Prog Brain Res. 2000;128:33–42. [PubMed]
  • Brederson JD, Jarvis MF. Homomeric and heteromeric P2X3 receptors in peripheral sensory neurons. Curr Opin Investig Drugs. 2008;9(7):716–725. [PubMed]
  • Chen M, Gu JG. A P2X receptor-mediated nociceptive afferent pathway to lamina I of the spinal cord. Mol Pain. 2005;1:4. [PMC free article] [PubMed]
  • Chen T, Koga K, Li XY, Zhuo M. Spinal microglial motility is independent of neuronal activity and plasticity in adult mice. Mol Pain. 2010;6:19. [PMC free article] [PubMed]
  • Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114(3):386–396. [PubMed]
  • Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB, Malcangio M. P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci. 2010;30(2):573–582. [PMC free article] [PubMed]
  • Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G. Tissue distribution of the P2X7 receptor. Neuropharmacology. 1997;36(9):1277–1283. [PubMed]
  • Contreras JE, Sanchez HA, Eugenin EA, Speidel D, Theis M, Willecke K, Bukauskas FF, Bennett MV, Saez JC. Metabolic inhibition induces opening of unapposed connexin 43 gap junction hemichannels and reduces gap junctional communication in cortical astrocytes in culture. Proc Natl Acad Sci U S A. 2002;99(1):495–500. [PubMed]
  • Cotrina ML, Lin JH, Alves-Rodrigues A, Liu S, Li J, Azmi-Ghadimi H, Kang J, Naus CC, Nedergaard M. Connexins regulate calcium signaling by controlling ATP release. Proc Natl Acad Sci U S A. 1998;95(26):15735–15740. [PubMed]
  • Cotrina ML, Nedergaard M. Physiological and pathological functions of P2X7 receptor in the spinal cord. Purinergic Signal. 2009;5(2):223–232. [PMC free article] [PubMed]
  • Cronin M, Anderson PN, Cook JE, Green CR, Becker DL. Blocking connexin43 expression reduces inflammation and improves functional recovery after spinal cord injury. Mol Cell Neurosci. 2008;39(2):152–160. [PubMed]
  • Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8(6):752–758. [PubMed]
  • DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain. 2001;90(1–2):1–6. [PubMed]
  • Dell'Antonio G, Quattrini A, Cin ED, Fulgenzi A, Ferrero ME. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum. 2002a;46(12):3378–3385. [PubMed]
  • Dell'Antonio G, Quattrini A, Dal Cin E, Fulgenzi A, Ferrero ME. Antinociceptive effect of a new P(2Z)/P2X7 antagonist, oxidized ATP, in arthritic rats. Neurosci Lett. 2002b;327(2):87–90. [PubMed]
  • Di Virgilio F, Ceruti S, Bramanti P, Abbracchio MP. Purinergic signalling in inflammation of the central nervous system. Trends Neurosci. 2009;32(2):79–87. [PubMed]
  • Di Virgilio F, Sanz JM, Chiozzi P, Falzoni S. The P2Z/P2X7 receptor of microglial cells: a novel immunomodulatory receptor. Prog Brain Res. 1999;120:355–368. [PubMed]
  • Donnelly-Roberts DL, Jarvis MF. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol. 2007;151(5):571–579. [PubMed]
  • Duan S, Anderson CM, Keung EC, Chen Y, Swanson RA. P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci. 2003;23(4):1320–1328. [PubMed]
  • Evans WH, De Vuyst E, Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J. 2006;397(1):1–14. [PubMed]
  • Farahani R, Pina-Benabou MH, Kyrozis A, Siddiq A, Barradas PC, Chiu FC, Cavalcante LA, Lai JC, Stanton PK, Rozental R. Alterations in metabolism and gap junction expression may determine the role of astrocytes as "good samaritans" or executioners. Glia. 2005;50(4):351–361. [PubMed]
  • Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci. 2004;24(9):2143–2155. [PubMed]
  • Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006;176(7):3877–3883. [PubMed]
  • Franke H, Grummich B, Hartig W, Grosche J, Regenthal R, Edwards RH, Illes P, Krugel U. Changes in purinergic signaling after cerebral injury -- involvement of glutamatergic mechanisms? Int J Dev Neurosci. 2006;24(2–3):123–132. [PubMed]
  • Friedle SA, Curet MA, Watters JJ. Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat CNS Drug Discov. 2010;5(1):35–45. [PMC free article] [PubMed]
  • Gallagher CJ, Salter MW. Differential properties of astrocyte calcium waves mediated by P2Y1 and P2Y2 receptors. J Neurosci. 2003;23(17):6728–6739. [PubMed]
  • Gao YJ, Ji RR. Targeting astrocyte signaling for chronic pain. Neurotherapeutics. 2010;7(4):482–493. [PMC free article] [PubMed]
  • Garre JM, Retamal MA, Cassina P, Barbeito L, Bukauskas FF, Saez JC, Bennett MV, Abudara V. FGF-1 induces ATP release from spinal astrocytes in culture and opens pannexin and connexin hemichannels. Proc Natl Acad Sci U S A. 2010;107(52):22659–22664. [PubMed]
  • Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, Jensen TK, Pei Y, Wang F, Han X, et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci. 2010;13(7):883–888. [PMC free article] [PubMed]
  • Gourine AV, Poputnikov DM, Zhernosek N, Melenchuk EV, Gerstberger R, Spyer KM, Gourine VN. P2 receptor blockade attenuates fever and cytokine responses induced by lipopolysaccharide in rats. Br J Pharmacol. 2005;146(1):139–145. [PubMed]
  • Gwak YS, Hulsebosch CE. Neuronal hyperexcitability: a substrate for central neuropathic pain after spinal cord injury. Curr Pain Headache Rep. 2011;15(3):215–222. [PubMed]
  • Hains BC, Waxman SG. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci. 2006;26(16):4308–4317. [PubMed]
  • Hua XY, Svensson CI, Matsui T, Fitzsimmons B, Yaksh TL, Webb M. Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur J Neurosci. 2005;22(10):2431–2440. [PubMed]
  • Huang C, Han X, Li X, Lam E, Peng W, Lou N, Torres A, Yang M, Mauricio Garre J, Tian G, et al. Critical Role Of Connexin 43 in Seconary Expansion of Traumatic Spinal Cord Injury. Journal of Neuroscience In Process. 2012 [PMC free article] [PubMed]
  • Hughes JP, Hatcher JP, Chessell IP. The role of P2X in pain and inflammation. Purinergic Signal. 2007;3(1–2):163–169. [PMC free article] [PubMed]
  • Hulsebosch CE, Hains BC, Crown ED, Carlton SM. Mechanisms of chronic central neuropathic pain after spinal cord injury. Brain Res Rev. 2009;60(1):202–213. [PMC free article] [PubMed]
  • Iglesias R, Dahl G, Qiu F, Spray DC, Scemes E. Pannexin 1: the molecular substrate of astrocyte "hemichannels". J Neurosci. 2009;29(21):7092–7097. [PMC free article] [PubMed]
  • John SA, Kondo R, Wang SY, Goldhaber JI, Weiss JN. Connexin-43 hemichannels opened by metabolic inhibition. J Biol Chem. 1999;274(1):236–240. [PubMed]
  • Kang J, Kang N, Lovatt D, Torres A, Zhao Z, Lin J, Nedergaard M. Connexin 43 hemichannels are permeable to ATP. J Neurosci. 2008;28(18):4702–4711. [PMC free article] [PubMed]
  • Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci. 2008;28(20):5189–5194. [PMC free article] [PubMed]
  • Kennedy C. P2X receptors: targets for novel analgesics? Neuroscientist. 2005;11(4):345–356. [PubMed]
  • Kobayashi K, Yamanaka H, Fukuoka T, Dai Y, Obata K, Noguchi K. P2Y12 receptor upregulation in activated microglia is a gateway of p38 signaling and neuropathic pain. J Neurosci. 2008;28(11):2892–2902. [PubMed]
  • Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature. 2007;446(7139):1091–1095. [PMC free article] [PubMed]
  • Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol. 2002;168(12):6436–6445. [PubMed]
  • Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, Watkins LR. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005;115(1–2):71–83. [PubMed]
  • Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 2003;20(10):1017–1027. [PubMed]
  • Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6(7):521–532. [PubMed]
  • Matasi JJ, Brumfield S, Tulshian D, Czarnecki M, Greenlee W, Garlisi CG, Qiu H, Devito K, Chen SC, Sun Y, et al. Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 1. Bioorg Med Chem Lett. 2011;21(12):3805–3808. [PubMed]
  • Matsuka Y, Ono T, Iwase H, Mitrirattanakul S, Omoto KS, Cho T, Lam YY, Snyder B, Spigelman I. Altered ATP release and metabolism in dorsal root ganglia of neuropathic rats. Mol Pain. 2008;4:66. [PMC free article] [PubMed]
  • Meme W, Calvo CF, Froger N, Ezan P, Amigou E, Koulakoff A, Giaume C. Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by beta-amyloid. FASEB J. 2006;20(3):494–496. [PubMed]
  • Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10(1):23–36. [PMC free article] [PubMed]
  • Minami M, Katayama T, Satoh M. Brain cytokines and chemokines: roles in ischemic injury and pain. J Pharmacol Sci. 2006;100(5):461–470. [PubMed]
  • Nagy JI, Patel D, Ochalski PA, Stelmack GL. Connexin30 in rodent, cat and human brain: selective expression in gray matter astrocytes, co-localization with connexin43 at gap junctions and late developmental appearance. Neuroscience. 1999;88(2):447–468. [PubMed]
  • Neary JT, Kang Y, Willoughby KA, Ellis EF. Activation of extracellular signal-regulated kinase by stretch-induced injury in astrocytes involves extracellular ATP and P2 purinergic receptors. J Neurosci. 2003;23(6):2348–2356. [PubMed]
  • Newman EA. Calcium increases in retinal glial cells evoked by light-induced neuronal activity. J Neurosci. 2005;25(23):5502–5510. [PMC free article] [PubMed]
  • Nie H, Zhang H, Weng HR. Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic rats. Neuroscience. 2010;170(3):901–912. [PMC free article] [PubMed]
  • Norenberg MD, Smith J, Marcillo A. The pathology of human spinal cord injury: defining the problems. J Neurotrauma. 2004;21(4):429–440. [PubMed]
  • O'Carroll SJ, Alkadhi M, Nicholson LF, Green CR. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. Cell Commun Adhes. 2008;15(1):27–42. [PubMed]
  • Parpura V, Scemes E, Spray DC. Mechanisms of glutamate release from astrocytes: gap junction "hemichannels", purinergic receptors and exocytotic release. Neurochem Int. 2004;45(2–3):259–264. [PubMed]
  • Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L, Takano T, Tian GF, Goldman SA, Nedergaard M. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci U S A. 2009;106(30):12489–12493. [PubMed]
  • Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003;306(2):624–630. [PubMed]
  • Retamal MA, Froger N, Palacios-Prado N, Ezan P, Saez PJ, Saez JC, Giaume C. Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia. J Neurosci. 2007;27(50):13781–13792. [PubMed]
  • Roh DH, Yoon SY, Seo HS, Kang SY, Han HJ, Beitz AJ, Lee JH. Intrathecal injection of carbenoxolone, a gap junction decoupler, attenuates the induction of below-level neuropathic pain after spinal cord injury in rats. Exp Neurol. 2010;224(1):123–132. [PubMed]
  • Rohr S. Role of gap junctions in the propagation of the cardiac action potential. Cardiovasc Res. 2004;62(2):309–322. [PubMed]
  • Rosenzweig ES, Courtine G, Jindrich DL, Brock JH, Ferguson AR, Strand SC, Nout YS, Roy RR, Miller DM, Beattie MS, et al. Extensive spontaneous plasticity of corticospinal projections after primate spinal cord injury. Nat Neurosci. 2010;13(12):1505–1510. [PMC free article] [PubMed]
  • Scemes E, Giaume C. Astrocyte calcium waves: what they are and what they do. Glia. 2006;54(7):716–725. [PMC free article] [PubMed]
  • Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain. 2003;103(3):249–257. [PubMed]
  • Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA. Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem. 2001;276(1):125–132. [PubMed]
  • Sorge RE, Trang T, Dorfman R, Smith SB, Beggs S, Ritchie J, Austin JS, Zaykin DV, Meulen HV, Costigan M, et al. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med. 2012;18(4):595–599. [PMC free article] [PubMed]
  • Spataro LE, Sloane EM, Milligan ED, Wieseler-Frank J, Schoeniger D, Jekich BM, Barrientos RM, Maier SF, Watkins LR. Spinal gap junctions: potential involvement in pain facilitation. J Pain. 2004;5(7):392–405. [PubMed]
  • Springer JE, Azbill RD, Knapp PE. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat Med. 1999;5(8):943–946. [PubMed]
  • Stout CE, Costantin JL, Naus CC, Charles AC. Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels. J Biol Chem. 2002;277(12):10482–10488. [PubMed]
  • Suadicani SO, Flores CE, Urban-Maldonado M, Beelitz M, Scemes E. Gap junction channels coordinate the propagation of intercellular Ca2+ signals generated by P2Y receptor activation. Glia. 2004;48(3):217–229. [PMC free article] [PubMed]
  • Tan AM, Zhao P, Waxman SG, Hains BC. Early microglial inhibition preemptively mitigates chronic pain development after experimental spinal cord injury. J Rehabil Res Dev. 2009;46(1):123–133. [PubMed]
  • Tang XQ, Heron P, Mashburn C, Smith GM. Targeting sensory axon regeneration in adult spinal cord. J Neurosci. 2007;27(22):6068–6078. [PubMed]
  • Teubner B, Michel V, Pesch J, Lautermann J, Cohen-Salmon M, Sohl G, Jahnke K, Winterhager E, Herberhold C, Hardelin JP, et al. Connexin30 (Gjb6)-deficiency causes severe hearing impairment and lack of endocochlear potential. Hum Mol Genet. 2003;12(1):13–21. [PubMed]
  • Theis M, de Wit C, Schlaeger TM, Eckardt D, Kruger O, Doring B, Risau W, Deutsch U, Pohl U, Willecke K. Endothelium-specific replacement of the connexin43 coding region by a lacZ reporter gene. Genesis. 2001;29(1):1–13. [PubMed]
  • Theis M, Jauch R, Zhuo L, Speidel D, Wallraff A, Doring B, Frisch C, Sohl G, Teubner B, Euwens C, et al. Accelerated hippocampal spreading depression and enhanced locomotory activity in mice with astrocyte-directed inactivation of connexin43. J Neurosci. 2003;23(3):766–776. [PubMed]
  • Theriault E, Frankenstein UN, Hertzberg EL, Nagy JI. Connexin43 and astrocytic gap junctions in the rat spinal cord after acute compression injury. J Comp Neurol. 1997;382(2):199–214. [PubMed]
  • Thompson RJ, Zhou N, MacVicar BA. Ischemia opens neuronal gap junction hemichannels. Science. 2006;3(5775):924–927. [PubMed]
  • Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S, Inoue K. P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J Neurosci. 2008;28(19):4949–4956. [PubMed]
  • Tsuda M, Inoue K, Salter MW. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci. 2005;28(2):101–107. [PubMed]
  • Tsuda M, Kuboyama K, Inoue T, Nagata K, Tozaki-Saitoh H, Inoue K. Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays. Mol Pain. 2009;5:28. [PMC free article] [PubMed]
  • Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424(6950):778–783. [PubMed]
  • Turner JA, Cardenas DD. Chronic pain problems in individuals with spinal cord injuries. Semin Clin Neuropsychiatry. 1999;4(3):186–194. [PubMed]
  • Wallraff A, Kohling R, Heinemann U, Theis M, Willecke K, Steinhauser C. The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. J Neurosci. 2006;26(20):5438–5447. [PubMed]
  • Wang X, Arcuino G, Takano T, Lin J, Peng WG, Wan P, Li P, Xu Q, Liu QS, Goldman SA, et al. P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med. 2004;10(8):821–827. [PubMed]
  • Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24(8):450–455. [PubMed]
  • Wu A, Green CR, Rupenthal ID, Moalem-Taylor G. Role of gap junctions in chronic pain. J Neurosci Res. 2012;90(2):337–345. [PubMed]
  • Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR. Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J Neurosci. 2003;23(9):3588–3596. [PubMed]